These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30718507)

  • 21. TRAIL death receptors and cancer therapeutics.
    Huang Y; Sheikh MS
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
    Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
    Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
    Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
    Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
    Qiao X; Wang X; Shang Y; Li Y; Chen SZ
    Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
    Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
    Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
    Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
    IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.
    Piechocki MP; Wu GS; Jones RF; Jacob JB; Gibson H; Ethier SP; Abrams J; Yagita H; Venuprasad K; Wei WZ
    Int J Cancer; 2012 Dec; 131(11):2562-72. PubMed ID: 22419388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
    Guillaume YC; Lethier L; André C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.
    Bertram H; Nerlich A; Omlor G; Geiger F; Zimmermann G; Fellenberg J
    Mod Pathol; 2009 Jul; 22(7):895-905. PubMed ID: 19305384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
    Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
    Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?
    van Roosmalen IA; Quax WJ; Kruyt FA
    Biochem Pharmacol; 2014 Oct; 91(4):447-56. PubMed ID: 25150214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Enhancement of glioma cell apoptosis induced by anti-human DR5/DR4 monoclonal antibodies by sub-toxic dose of doxorubicin in human].
    Zhuang GH; Song YG; Bi SL; Du BR; Zhu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):120-3. PubMed ID: 17286903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.
    Li M; Wu Y; Qiu Y; Yao Z; Liu S; Liu Y; Shi J; Zheng D
    Mol Ther; 2012 Jan; 20(1):46-53. PubMed ID: 21934654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.
    Chuntharapai A; Dodge K; Grimmer K; Schroeder K; Marsters SA; Koeppen H; Ashkenazi A; Kim KJ
    J Immunol; 2001 Apr; 166(8):4891-8. PubMed ID: 11290766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
    Fu L; Lin YD; Elrod HA; Yue P; Oh Y; Li B; Tao H; Chen GZ; Shin DM; Khuri FR; Sun SY
    Mol Cancer; 2010 Dec; 9():315. PubMed ID: 21172010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
    Shivange G; Mondal T; Lyerly E; Bhatnagar S; Landen CN; Reddy S; Kim J; Doan B; Riddle P; Tushir-Singh J
    Cell Rep; 2021 Nov; 37(5):109953. PubMed ID: 34731630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.